BioMarin Pharmaceutical Inc. (BMRN) Investor Relations Documents

BioMarin Pharmaceutical Inc. (BMRN) investor relations documents from the company's IR site: 9 presentations, 31 press releases; latest deck 2026-08-06. Read in-app with summaries. First-party data.

Presentation: BioMarin reported Q2 2026 financial results, raising full-year guidance to $3.875B–$3.925B in revenue and $4.90–$5.10 in Non-GAAP Diluted EPS.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-10Press releaseBioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM
2026-08-06Earnings deckPresentation
2026-08-06Press releaseBioMarin Reports Second Quarter 2026 Financial and Operating Results
2026-08-05Press releaseBioMarin Pharmaceutical Second Quarter 2026 Conference Call
2026-07-30Press releaseBioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30p
2026-07-27Press releaseBioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Ne
2026-07-13Press releaseU.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vo
2026-06-16Press releaseBioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
2026-05-20Press releaseBioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
2026-05-18Press releaseBioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
2026-05-04Press releaseBioMarin Reports First Quarter 2026 Financial and Operating Results
2026-05-04Earnings deckPresentation of Q1 2026, PDF file, (opens in new window)
2026-05-04Press releasePress Release of Q1 2026, PDF file, (opens in new window)
2026-05-02Press releaseBioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and
2026-04-27Press releaseBioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
2026-04-27Press releaseBioMarin Completes Acquisition of Amicus Therapeutics
2026-04-21Press releaseBioMarin Announces Board Leadership Transition
2026-03-12Press releaseBioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and A
2026-02-27Press releaseU.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Ol
2026-02-24Press releaseBioMarin to Participate in Four Upcoming Investor Conferences in March
2026-02-23Earnings deckPresentation Open Event Link, PDF file, February 23, 2026, (opens in new window)
2026-02-23Press releasehttps://www.prnewswire.com/news-releases/biomarin-reports-fourth-quarter-and-full-year-2025-financial-and-operating-resu
2026-02-23Press releasePress Release Open Event Link, PDF file, February 23, 2026, (opens in new window)
2026-02-23Press releaseBioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
2026-02-17Press releaseBioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23,
2026-02-12Press releaseBioMarin Announces Closing of Private Offering of Senior Notes
2026-01-29Press releaseBioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term
2026-01-26Press releaseBioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
2026-01-12Press releaseBioMarin Appoints Arpit Davé Chief Digital and Information Officer
2026-01-12PresentationPresentation Open Event Link, PDF file, January 12, 2026, (opens in new window)
2026-01-08Press releaseBioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm
2025-10-27Earnings deckPresentation of Q3 2025 Report, (opens in new window)
2025-08-01Earnings deckPresentation of Q2 2025 Report, (opens in new window)
2025-04-30Earnings deckPresentation of First Quarter 2025, PDF file, (opens in new window)
2025-02-19Earnings deckPresentation of Fourth Quarter 2024, PDF file, (opens in new window)
2025-02-19Press releasePress Release of Fourth Quarter 2024, PDF file, (opens in new window)
2025-01-13Presentation43rd Annual J.P. Morgan Healthcare Conference
2024-10-29Press releasePress Release of Third Quarter 2024, PDF file, (opens in new window)
2024-08-05Press releasePress Release of Second Quarter 2024, PDF file, (opens in new window)
2024-04-24Press releasePress Release of First Quarter 2024, PDF file, (opens in new window)

BMRN overview · BMRN earnings · BMRN financials · BMRN KPIs · BMRN documents · BMRN ownership · BMRN peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.